EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor

Ping Zhou, Yiyun Fu, Yuan Tang, Lili Jiang, Weiya Wang

PeerJ · 16.02.2024 · 12 · e16923

DOI: 10.7717/peerj.16923 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, online erschienen am 16.02.2024. Verfasst von Ping Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thoracic Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University, Sichuan Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a distinct clinicopathological entity with an aggressive clinical course. Additionally, SMARCA4/BRG1 deficiency can be observed in a few patients with non-small cell lung cancer (NSCLC). We aimed to compare the clinicopathological, immunohistochemical and prognostic features of SMARCA4-deficient NSCLC (SMARCA4-dNSCLC) with those of thoracic SMARCA4-UT.

Methods

Patients with BRG1-deficient tumors in the lung or thorax were enrolled in the study from the Department of Pathology of West China Hospital, Sichuan University, from January 2014 to June 2022. We retrospectively collected the clinicopathological and immunohistochemical features and outcomes of these patients.

Results

Seventy-two patients had tumors in the lung or thorax with BRG1-deficient expression, including 52 patients with SMARCA4-dNSCLC and 20 patients with thoracic SMARCA4-UT. Among the patients with SMARCA4-dNSCLC, 98.1% were male, 85.7% were smokers, and 79.5% (35/44) had tumor-node-metas­tasis (TNM) III-IV tumors. Among the patients with thoracic SMARCA4-UT, all were males who smoked, and 93.75% (15/16) had TNM III-IV tumors. Pure solid architecture and necrosis were the predominant pathological features. Rhabdoid morphology was observed in some SMARCA4-dNSCLCs (10/52, 19.2%) and thoracic SMARCA4-UTs (11/20, 55%). In most patients with thoracic SMARCA4-UT, the tumors exhibited scattered weak expression or negative expression of epithelial markers, and positive expression of CD34 and Syn. Overall survival (OS) and progression-free survival (PFS) were not significantly different between patients with SMARCA4-dNSCLC and patients with thoracic SMARCA4-UT ( p = 0.63 and p = 0.20, respectively).

Conclusions

Thoracic SMARCA4-DTs include SMARCA4-dNSCLC and thoracic SMARCA4-UT. Both have overlapping clinicopathological features and poor prognosis. We hypothesize that thoracic SMARCA4-UT may be the undifferentiated or dedifferentiated form of SMARCA4-dNSCLC. However, further studies with larger cohorts and longer follow-up periods are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsThoracic NeoplasmsHumansMaleFemaleRetrospective StudiesBiomarkers, TumorDNA HelicasesNuclear ProteinsTranscription Factors

Stichwörter der Autor:innen

BRG1NSCLCSMARCA4SWI/SNFUndifferentiated tumor

Substanzen

Biomarkers, TumorSMARCA4 protein, humanDNA HelicasesNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Förderung

  • Project for Disciplines of Excellence-Clinical Research Incubation Project
  • West China Hospital, Sichuan University
  • Sichuan Science and Technology Program
  • Sichuan University

Zitieren

APA

Zhou, P., Fu, Y., Tang, Y., Jiang, L., & Wang, W. (2024). Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor. PeerJ, 12, e16923. https://doi.org/10.7717/peerj.16923

Vancouver

Zhou P, Fu Y, Tang Y, Jiang L, Wang W. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor. PeerJ. 2024;12:e16923. doi:10.7717/peerj.16923

BibTeX
@article{Zhou2024,
  author = {Zhou, Ping and Fu, Yiyun and Tang, Yuan and Jiang, Lili and Wang, Weiya},
  title = {Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor},
  journal = {PeerJ},
  year = {2024},
  volume = {12},
  pages = {e16923},
  doi = {10.7717/peerj.16923}
}
Kostenlos starten →